IDEXX:
The Vet Clinic's Other Employee

Fewer American pets walked into a vet clinic this spring than last spring. The same clinics sent IDEXX about ten percent more money.

The number that reads like a typo

According to the IDEXX Q2 2026 earnings call, in the three months to June 2026, US same-store clinical visits fell 1.3%. Wellness visits, the routine annual check, fell 3.4%. Over the same three months IDEXX's US recurring diagnostics revenue grew close to 10%, a gap of roughly 1,100 basis points between what its customers were doing and what IDEXX was earning from them.

Companies that sell into a shrinking market usually shrink with it. This one did not. Why? Let’s find out.

Where the extra ten percent came from

Start with what IDEXX sells. Of $1,217 million in second-quarter revenue, $975 million came from one line called CAG Diagnostics recurring revenue: the test cartridges, the lab work, and the assays that a clinic buys again next week. That is four dollars in every five.

Now look at the line that fell. Revenue from selling analyzers dropped 20% on an organic basis in the quarter. Consumables for those analyzers rose 14%. Lab revenue, according to the IDEXX Q2 2026 earnings call, rose more than 10%.

The hardware business went backward, and the company grew anyway. The strange number is real because the machine stopped being the product a long time ago.

There is a second reason, and it is the one worth stealing. IDEXX grows by getting more testing into the appointments that already happen. Management calls this visit quality, and the aging pet population feeds it: dogs and cats over five years old kept growing as a share of appointments through the quarter, and older animals get tested more often.

Portland, 1983

IDEXX opened as AgriTech Systems with five employees in Portland, Maine, and made its first sale to a poultry producer in Glastonbury, Connecticut. The name changed to IDEXX later in the decade. The company moved to Westbrook, Maine, and went public in 1991 with an offering of 1,600,000 shares.

The early products were test kits, sold one at a time to whoever would buy them.

The change came with the analyzers. Before them, a vet who wanted bloodwork drew the sample, packed it for a courier, and told the owner to expect a call in a day or two. The dog went home untreated. The owner sometimes did not come back. Every step in that chain was a place where the test could fall out of the visit entirely.

An analyzer on the counter collapses the chain into one appointment. The vet runs the panel while the owner waits, reads the result, and treats the animal before it leaves the room. Put the machine in the room, and the consumables follow forever.

The arithmetic of one box

Each IDEXX inVue Dx analyzer generates between $3,500 and $5,500 a year in consumables. The company placed 1,602 of them in the quarter, taking the installed base past 9,000 since launch, and its wider premium instrument base grew 11% year on year.

That is the whole model in one line of arithmetic. A placement is a subscription that has not been priced as one. "Each new placement is a long-term platform investment," chief executive Michael Erickson told analysts in August 2026.

Two conditions make the arithmetic hold. The consumables have to be proprietary to the box, and the box has to stay. Global customer retention for the diagnostics business runs in the high 90s.

Why they add tests without adding price

There are nearly 80,000 Catalyst chemistry analyzers in clinics around the world. In June 2026 IDEXX built its SDMA kidney marker into the standard Catalyst cartridges for every North American customer, so the test now runs by default in the most common panel.

Its cancer screen follows the same logic. Cancer Dx costs about $15 when run inside a lab profile, and the mast cell tumor version arriving in late 2026 carries no price increase at all

Pricing a new test low enough to disappear into a routine panel buys something better than margin per test. It buys frequency. And the headroom is enormous: only about one in ten US wellness visits currently includes bloodwork at all.

Four moves for your own installed base

If you have a business of your own, here are four moves you can try.

1. Find what is already sitting in the customer's room

List everything you have placed with customers that they touch weekly: hardware, a template, a dashboard, a piece of your process living inside theirs. Pick the one with the highest weekly usage. You have found it when you can state the annual revenue that one unit produces without opening a spreadsheet.

2. Price the follow-on so it enters the routine

Model your attach rate at half your current price for the add-on. If volume more than doubles, the low price is the better business. IDEXX ships a cancer screen at fifteen dollars because a test inside a routine panel gets run on every eligible patient.

3. Ship capability, not new units

New cell morphologies land on every connected InVue Dx worldwide with no action required from the practice. Build one upgrade this quarter that reaches existing customers automatically. The signal is revenue per installed unit rising in a quarter when you placed nothing new.

4. Track your growth premium

Put your revenue growth next to your customers' underlying activity, monthly. IDEXX ran 1,100 basis points ahead of clinical visits. A premium that widens for two quarters means you are selling more to each customer. A premium that closes means you are only riding their volume.

What the next decade turns on

Nine in ten routine visits still end without a blood draw. IDEXX has spent forty years making the test easier to run than to skip, and the remaining growth sits inside appointments that already happen.